For the Inventor, By the Inventor

Enter assignee name

Rockville, MD, United States of America

Supernus Pharmaceuticals, Inc.

USPTO Granted Patents = 78

CIPO Patents = 12

EPO Patents = 26

Trademarks = 12

Forward Citations = 462

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Padmanabh P Bhatt (45 out of 46 patents)

Likan Liang (25 out of 26 patents)

Argaw Kidane (23 out of 24 patents)

4. Michael L Vieira (17 out of 17 patents)

5. Rong-Kun Chang (15 out of 24 patents)

6. Kevin Edwards (14 out of 14 patents)

7. Arash Raoufinia (11 out of 16 patents)

8. Hua Wang (10 out of 10 patents)

9. Niraj Shah (10 out of 10 patents)

10. Christopher D Breder (8 out of 56 patents)

11. Austin B Huang (7 out of 8 patents)

12. Martin Hanbauer (6 out of 6 patents)

13. Zarghun Nazir (6 out of 8 patents)

14. Peter Hildebrand (6 out of 9 patents)

15. Attilia Figini (6 out of 7 patents)

Core Competencies:

Isoindoles Derivatives

Substituted Morpholines

Attention Deficit Hyperactivity Disorder

CNS Disorders

Modified Release Preparations

Oxcarbazepine Derivatives

Sustained Release Formulations

Topiramate Compositions

Viloxazine Formulations

Drug Abuse Potential

Osmotic Drug Delivery

Molindone Production

78 patents: Sort by Forward Citations

1. 12454535 - Substituted derivatives of isoindoles (2025-10-28),

2. 12215097 - Derivatives of substituted morpholines and uses thereof (2025-02-04),

3. 12121523 - Method of treatment of attention deficit/hyperactivity disorder (ADHD) (2024-10-22),

4. 11964951 - Process of making derivatives of substituted morpholines (2024-04-23),

5. 11919889 - Derivatives of substituted morpholines and uses thereof (2024-03-05),

6. 11911368 - Method of treatment of CNS disorders (2024-02-27),

7. 11896599 - Modified release preparations containing oxcarbazepine and derivatives thereof (2024-02-13),

8. 11638708 - Method of treatment of aggression (2023-05-02),

9. 11634415 - Derivatives of substituted morpholines and uses thereof (2023-04-25),

10. 11458143 - Method of treatment of attention deficit/hyperactivity disorder (ADHD) (2022-10-04),

11. 11351120 - Use of higher doses of modified release huperzine formulations (2022-06-07),

12. 11324753 - Method of treatment of attention deficit/hyperactivity disorder (ADHD) (2022-05-10),

13. 11166960 - Modified release preparations containing oxcarbazepine and derivatives thereof (2021-11-09),

14. 11117862 - Methods of producing molindone and its salts (2021-09-14),

15. 11077114 - Stabilized formulations of CNS compounds (2021-08-03),

Supernus Pharmaceuticals, Inc. is a leading specialty pharmaceutical company focused on developing and commercializing innovative products for the treatment of central nervous system diseases. With a deep commitment to improving patients' lives, Supernus aims to provide novel therapies that address unmet medical needs. The company's portfolio includes a range of products targeting multiple neurological disorders, such as epilepsy and attention-deficit hyperactivity disorder (ADHD). Through its unique technology platforms and strong research capabilities, Supernus continues to drive scientific innovation and create value for healthcare providers and patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

78 Patents

#5 in Rockville, MD

#38 in Maryland

#4,548 in US

#9,298 in the World

Rockville, MD, United States of America

Supernus Pharmaceuticals, Inc.

Forward Citations = 462

40 inventors:

Padmanabh P Bhatt (45 out of 46 patents)

Likan Liang (25 out of 26 patents)

Argaw Kidane (23 out of 24 patents)

4. Michael L Vieira (17 out of 17 patents)

5. Rong-Kun Chang (15 out of 24 patents)

Please report any incorrect information to support@idiyas.com

Loading…